Skip to content
value.today

Retractable Technologies, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Medical Instruments: $75 M to $254 M, median $133 MPrice to bookPrice to book of Medical Instruments: $147 M to $492 M, median $330 M$0 M$133 M$266 M$398 M$531 MMarket value $18 M

Your own DCF model

A full discounted-cash-flow model of Retractable Technologies, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Instruments

Multiples of its companies with a market value at most 60 days old, times Retractable Technologies, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)The companyApplied toValue (25th to 75th)Companies
Price to sales2.0× / 3.5× / 6.6×0.5×revenue $38 M$75 M to $254 M23
Price to book2.0× / 4.4× / 6.6×0.2×book equity $74 M$147 M to $492 M23

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Retractable Technologies, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

0.5×

Now below its median of 0.6×, in the bottom quarter of its range; range 0.3× to 8.7× over 20 months.

0×2×4×7×9×2020202120222023202420252026Price to sales 1×Median 1×

Price to book

0.2×

Now below its median of 0.3×, in the bottom quarter of its range; range 0.2× to 12.7× over 20 months.

0×3×6×10×13×2020202120222023202420252026Price to book 0×Median 0×

as of Oct 28, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 28, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$38 M$-13 M$-7 M——$-2 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$33 M$-12 M$-12 M$1 M$-13 M$-3 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$44 M$-7 M$3 M$1 M$2 M$-11 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$95 M$5 M$17 M$17 M$-0 M$-18 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$188 M$56 M$33 M$58 M$-26 M$-27 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$82 M$24 M$19 M$21 M$-2 M$-14 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $18 M on Oct 28, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.